TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03971851

Intervention type: OTHER
Intervention: Frailty risk groups
Description: Patients older than 65 will be separated into groups of varying frailty risk
Study: NCT00450281

Intervention type: OTHER
Intervention: fluorescent antibody technique

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Intervention type: OTHER
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Intervention type: OTHER
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Intervention type: OTHER
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables

Intervention type: PROCEDURE
Intervention: study of high risk factors

Intervention type: PROCEDURE
Intervention: study of high risk factors

Intervention type: PROCEDURE
Intervention: study of high risk factors

Intervention type: PROCEDURE
Intervention: study of high risk factors
Study: NCT00607009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIVE
Description: ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
Study: NCT00585247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Study: NCT01130012

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle: diet and exercise
Description: Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Close follow-up: reporting diaries of food and exercise
Description: Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
Study: NCT02599038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serine supplementation
Description: Serine supplementation (200 mg/kg/day)
Study: NCT02934659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atlas(TM) Knee System
Description: The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
Study: NCT04933994

Intervention type: DEVICE
Intervention: computed Tomography
Description: All cases were detected with computed Tomography
Study: NCT01730469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT1001 150 mg
Description: AT1001 150mg is available as a capsule
Study: NCT00382252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study: NCT03638297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody + cox inhibitor
Description: BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency.
Study: NCT02837783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, one daily
Study: NCT00920712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weiqi decotion
Description: Decoction ,two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Weiqi decotion
Description: Decoction ,two times a day
Study: NCT00663169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: 10 mg/kg intravenous infusion 250 mL over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 12 mg intravenous infusion 50 mL over 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo matching canakinumab
Description: 5% glucose in water intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo matching dexamethasone
Description: Placebo intravenous infusion.
Study: NCT00541710

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: genistein
Description: pills of 27 mg, twice per day for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: sugar pills twice per day for 12 months
Study: NCT00867724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aer-O-Scope Colonoscopy
Description: Screening Colonoscopy
Study: NCT03645798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three good things therapy
Description: To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal psychological instruction
Description: Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
Study: NCT03153969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHOFU Beautifil II LS
Description: Placed under manufacturer's instructions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M/ESPE Filtek Supreme
Description: Placed under manufacturer's instructions
Study: NCT00353262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 7.5mg/kg iv (cycle 3 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv (cycles 1, 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid (cycles 1, 2 and 3)
Study: NCT01239004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: 6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
Study: NCT02067871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
Study: NCT00787059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6
Description: Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
Study: NCT00504023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
Study: NCT02067871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
Study: NCT00504023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Punch biopsy and photography will be performed at the baseline and 12 week time points.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
Study: NCT02639637

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
Study: NCT00787059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose (3%)
Study: NCT02755155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human serum albumin infusion 4%
Description: Continuous infusion of 15mL/kg of bodyweight over 24h/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin infusion 20%
Description: Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
Study: NCT02069431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin spray
Description: Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo spray
Description: placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
Study: NCT00313339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-coronary infusion
Description: In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
Study: NCT01467414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily for 6 days
Study: NCT04431583

Intervention type: PROCEDURE
Intervention: Bariatric surgery- single surgeon service

Intervention type: PROCEDURE
Intervention: Bariatric surgery- multiple surgeon + multidisciplinary team approach

Intervention type: PROCEDURE
Intervention: Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach
Study: NCT03536273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group Exercises
Description: For 12 weeks, 3 repetitions per week
Study: NCT02639637

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Neuropeptide Y
Description: During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Neuropeptide Y
Description: During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Enalaprilat
Description: Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Enalaprilat
Description: Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 160mg
Description: Valsartan 160 mg/d for 7 days prior to one of the study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 160mg
Description: Valsartan 160 mg/d for 7 days prior to one of the study days.
Study: NCT03844139

Intervention type: DEVICE
Intervention: Feeding pump and glycerin syringe
Description: The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.

Intervention type: DEVICE
Intervention: Feeding pump and glycerin syringe
Description: The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
Study: NCT02329145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation
Study: NCT01307397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
Study: NCT04298801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing
Description: A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-directed diagnostic testing
Description: Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician-directed diagnostic testing
Description: Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
Study: NCT01362205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive placebo (normal saline)
Study: NCT02352675

Intervention type: OTHER
Intervention: Intraoperative Blood Sample
Description: Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis

Intervention type: OTHER
Intervention: Intraoperative Blood Sample
Description: Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
Study: NCT02879305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Study: NCT01236846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Yogurt Drink
Description: Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Yogurt Drink
Description: Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Yogurt Drink
Description: Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain Yogurt Drink
Description: Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
Study: NCT03640195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure
Description: Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day.
Study: NCT02310113

Intervention type: OTHER
Intervention: NIRS
Description: Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
Study: NCT01053325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Description: Daily prophylaxis with cotrimoxazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole prophylaxis
Description: Daily prophylaxis with cotrimoxazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Description: Daily prophylaxis with cotrimoxazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP IPT
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine
Study: NCT03665207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
Study: NCT04039698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine monitoring and teleconsultation by video calls
Study: NCT01053325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP IPT
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine
Study: NCT02097069

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic acid
Description: Folic acid 400 mcg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: myo-inositol 2000 mg twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Chiro-inositol
Description: D-chiro inositol 250 mg twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus D-chiro inositol
Description: Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
Study: NCT04241952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Bedcycling